Muraglitazar

Summary

Muraglitazar (CHEMBL186179) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 10
• Chemistry: 516.5 Da · C29H28N2O7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL186179
Name	Muraglitazar
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	206044
Molecular formula	C29H28N2O7
Molecular weight	516.5
InChIKey	IRLWJILLXJGJTD-UHFFFAOYSA-N

SMILES: CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3=CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC

IUPAC name: 2-[(4-methoxyphenoxy)carbonyl-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid

Also known as: BMS-298585, MK-0478, MK0478, Muraglitazar, muraglitazar, MURAGLITAZAR, SID170466259, Muraglitizar

Parent form; salt/anhydrous children: CHEMBL557580, CHEMBL3527055

Patent coverage: 444 distinct patent families (1,191 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Peroxisome proliferator-activated receptor gamma, Peroxisome proliferator-activated receptor alpha.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PPARG	8.52	EC50	3	nM	CHEMBL_ACT_18346878
PPARG	7.8	EC50	16	nM	CHEMBL_ACT_26335916
PPARG	7.46	EC50	35	nM	CHEMBL_ACT_15159432
PPARG	7.46	EC50	35	nM	CHEMBL_ACT_2269627
PPARG	7.4	EC50	40	nM	CHEMBL_ACT_2173266
PPARA	7.3	EC50	50	nM	CHEMBL_ACT_26335917
PPARG	7.05	EC50	90	nM	CHEMBL_ACT_2503981
PPARG	7	EC50	100	nM	CHEMBL_ACT_12188774
PPARG	6.96	EC50	110	nM	CHEMBL_ACT_1518994
PPARG	6.92	EC50	120	nM	CHEMBL_ACT_1463604
PPARG	6.92	IC50	120	nM	CHEMBL_ACT_18758364
PPARG	6.82	EC50	153	nM	CHEMBL_ACT_2483469
PPARA	6.82	EC50	150	nM	CHEMBL_ACT_2503972
PPARG	6.72	IC50	190	nM	CHEMBL_ACT_1518993
PPARA	6.72	IC50	190	nM	CHEMBL_ACT_2173264
PPARA	6.62	EC50	240	nM	CHEMBL_ACT_1463603
PPARA	6.6	IC50	250	nM	CHEMBL_ACT_1518981
PPARG	6.6	IC50	250	nM	CHEMBL_ACT_2173265
PPARA	6.52	EC50	300	nM	CHEMBL_ACT_12188797
PPARA	6.5	EC50	320	nM	CHEMBL_ACT_1518991
PPARA	6.22	EC50	595	nM	CHEMBL_ACT_18346839
PPARA	5.85	EC50	1410	nM	CHEMBL_ACT_15160460
PPARA	5.85	EC50	1410	nM	CHEMBL_ACT_2173267
PPARA	5.85	EC50	1410	nM	CHEMBL_ACT_2269629
PPARA	5.39	EC50	4110	nM	CHEMBL_ACT_2483435

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	3	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE3	8
PHASE2/PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00094991	PHASE3	COMPLETED	Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
NCT00095030	PHASE3	COMPLETED	Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone
NCT00106808	PHASE3	COMPLETED	Study of Muraglitazar Versus Pioglitazone in Type 2 Diabetes
NCT00130806	PHASE3	TERMINATED	An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)
NCT00162175	PHASE3	COMPLETED	PPAR-COMBO With Sulfonylurea
NCT00162240	PHASE3	COMPLETED	PPAR - Combination With Metformin
NCT00240370	PHASE3	COMPLETED	A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
NCT00240383	PHASE2/PHASE3	COMPLETED	Dose Ranging Study With LT, Monotherapy, PPAR
NCT00245388	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of BMS-298585 Alone or in Combination With Pravastatin in Subjects With Mixed Dyslipidemia
NCT00246987	PHASE3	COMPLETED	A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline, but PharmGKB curates 3 clinical and 3 variant annotation(s) for this drug (gene-keyed; see PharmGKB).

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).